Ascendia

  MARKET NEWS

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis & Discloses Clinical Development Plan
TTP introduces Cellular Origins, Focused on Delivering Ccalable Manufacture of Cell & Gene Therapies
Scaling Up Capacity, Eitan Medical Opens New Manufacturing Facility Bolstered by Semi-Automated Production Lines
Global CDMO Adare Pharma Solutions Harmonizing Quality With Veeva Vault Quality Suite
Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

  FEATURED EDITORIAL

  COMPANY PROFILE

Micropore Technologies is a global process technology and service provider to the pharmaceutical industry featuring patented crossflow technology for the commercially scalable development of topical and sterile injectable drug products. Originally spun-out of Loughborough University’s internationally renowned chemical engineering department, the company’s global headquarters and technical center are located at Wilton Center, UK with offices and operations in the USA, India, South Korea & Japan supporting over a hundred clients and strategic partners. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access

Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access

CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas have recently signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project….

Lonza Completes Expansion to Solid Form Services Facility at Oregon Site

Lonza Completes Expansion to Solid Form Services Facility at Oregon Site

The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules….

Ethicann & Catalent Sign Development & License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments

Ethicann & Catalent Sign Development & License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments

Catalent and Ethicann Pharmaceuticals Inc. recently announced the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s….

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Pheno Therapeutics Limited. recently announced it has entered into an exclusive worldwide license agreement with UCB. The agreement grants Pheno Therapeutics access and rights to….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 25 – Bioavailability
February 1 – Analytical Testing